The ‘Increasing Access to Biosimilar Act of 2023’ (HR 1352) was introduced into the US House of Representatives. The bill, if passed by Congress, would ‘require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program’. Its purpose is ‘to evaluate the benefits of providing a shared savings payment for biosimilar biological products’. The bill has been praised by the Biosimilars Forum.
Soft Close, Hard Lessons: Full Court Reinforces Purposive Construction of Patent Claims and the Disclosure Requirements for Divisional Patents
Glass Hardware Australia Pty Ltd v TCT Group Pty Ltd [2024] FCAFC 95 Date of decision: 17 July 2024 Body: Full Court of the Federal Court of...